NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
The summary for the NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional): This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission. The NHLBI expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention and/or treatment of heart, lung, blood, and sleep disorders. In contrast to the study start up or preparation phase of NHLBI funding opportunities for clinical trials (as described at https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/clinical-trials-optimization), the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a Phase II-IV clinical trial. Regardless of the results of the R34, support of the proposed future clinical trial will require a new application.
| Federal Grant Title: | NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) |
| Federal Agency Name: | National Institutes of Health (HHS-NIH11) |
| Grant Categories: | Health |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | PAR-25-032 |
| Type of Funding: | Grant |
| CFDA Numbers: | 93.233, 93.837, 93.838, 93.839, 93.840 |
| CFDA Descriptions: | Information not provided |
| Current Application Deadline: | January 7th, 2027 |
| Original Application Deadline: | January 7th, 2027 |
| Posted Date: | December 18th, 2024 |
| Creation Date: | December 18th, 2024 |
| Archive Date: | February 12th, 2027 |
| Total Program Funding: | |
| Maximum Federal Grant Award: | |
| Minimum Federal Grant Award: | |
| Expected Number of Awards: | |
| Cost Sharing or Matching: | No |
| Last Updated: | December 18th, 2024 |
- Applicants Eligible for this Grant
- State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
- Additional Information on Eligibility
- Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- https://grants.nih.gov/grants/guide/pa-files/PAR-25-032.html
- Grant Announcement Contact
- NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires. - Similar Government Grants
- • Limited Competition: Stimulating Access to Research in Residency Transition Scholar (StARR...
- • Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiologi...
- • Single Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabet...
- • Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U0...
- • NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Pare...
- • Ancillary Studies in Clinical Trials (R01)
- • Opportunity PA-08-021
- • Research Demonstration and Dissemination Grants (R18)
- More Grants from the National Institutes of Health
- • HIV/AIDS Clinical Trials Network Statistical and Data Management Centers (UM1 Clinical Tri...
- • HIV/AIDS Clinical Trials Network Laboratory Centers (UM1 Clinical Trial Required)
- • HIV/AIDS Clinical Trials Network Clinical Trials Units (UM1 Clinical Trial Required)
- • HIV/AIDS Clinical Trials Network Leadership and Operations Centers (UM1 Clinical Trial Req...
- • Advancing Real-World Effectiveness Evidence for Rapid-Acting Psychotropic Interventional D...
